XERS Xeris Pharmaceuticals Inc.

5.75
-0.29  -5%
Previous Close 6.04
Open 6.11
Price To Book 3.55
Market Cap 155,221,578
Shares 26,995,057
Volume 336,588
Short Ratio
Av. Daily Volume 236,848
Stock charts supplied by TradingView

NewsSee all news

  1. Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise

    Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting

  2. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  3. Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

    All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and

  4. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  5. Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference

    MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program discontinued based on Phase 2

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data showed no statistically significant differences between the treatment arms. Program to be discontinued - November 21, 2019.
Continuous glucagon
Hypoglycemia-Associated Autonomic Failure
Phase 3 trial to be initiated 2H 2019.
Continuous glucagon
Congenital Hyperinsulinism
Phase 2b data due 4Q 2019. Moved to 1Q 2020 due to no update.
Self administered glucagon
Exercise-Induced Hypoglycemia
Phase 2b data released December 10, 2019. Further data due 1H 2020.
Self administered glucagon
Post-Bariatric Hypoglycemia
FDA Approval announced September 10, 2019.
Glucagon Rescue Pen
Severe hypoglycemia
Phase 2 trial to be initiated 2H 2019.
Diazepam
Seizures
Phase 2 data due 1H 2020.
Pramlintide and insulin
Type 1 diabetes

Latest News

  1. Xeris Pharmaceuticals Announces Positive Results from the In-Clinic Stage of a Phase 2 Study of Its Developmental Ready-To-Use (RTU) Glucagon in Patients at Risk of Hypoglycemia During and after Aerobic Exercise

    Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting

  2. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHICAGO, Dec. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  3. Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery

    All subjects successfully self-administered a mini dose of RTU glucagon Rebound hypoglycemia observed more frequently in the placebo arm and with oral glucose tablet use Subcutaneous RTU glucagon is safe and

  4. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CHICAGO, Nov. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  5. Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference

    MAA submitted to EMA of liquid stable glucagon for severe hypoglycemiaGVOKE™ PFS launch underwayGVOKE HypoPen™ expected to launch July 2020CHI program shifts to Expanded AccessHAAF program discontinued based on Phase 2

  6. Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights

    Gvoke™ (glucagon injection) pre-filled syringe (PFS) - now available by prescription MAA for ready-to-use glucagon on track for submission to EMA by year-end Data from three Phase 2 studies expected by year-end

  7. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  8. Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors

    CHICAGO, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use

  9. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    CHICAGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  10. Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes

    Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations,

  11. Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank

    Provides up to three years of interest only and extension of maturity date Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop

  12. Xeris Pharmaceuticals Receives U.S. FDA Approval for GVOKE™ (glucagon), the First Ready-to-use Stable Liquid Glucagon for Severe Hypoglycemia

    First approval for Xeris is based on positive efficacy and safety results from multiple clinical studies GVOKE is the first premixed, prefilled, premeasured liquid glucagon offering ease of use for pediatric and adult

  13. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    CHICAGO, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable

  14. Xeris Pharmaceuticals to Present at Two September Healthcare Conferences

    CHICAGO, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use